Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients.

IF 1.2 Q4 ONCOLOGY
Hepatic Oncology Pub Date : 2016-08-01 Epub Date: 2016-08-19 DOI:10.2217/hep-2016-0007
Jordi Bruix
{"title":"Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients.","authors":"Jordi Bruix","doi":"10.2217/hep-2016-0007","DOIUrl":null,"url":null,"abstract":"<p><p><b>Dr Jordi Bruix* speaks to Laura Dormer, Editorial Director:</b> Dr Jordi Bruix is the Head of the Barcelona Clinic Liver Cancer (BCLC) group at the Hospital Clinic (University of Barcelona, Spain) and Director of the Network for Research in Liver and Digestive Disease (CIBEREHD) in the Spanish Research Institute. His research has changed the diagnosis and treatment of liver cancer. Major highlights include: development of the BCLC staging and treatment; development of diagnostic criteria for hepatocellular carcinoma; identification of the value of portal pressure in predicting prognosis after resection; and acting as principal investigator of the Phase III trials that have shown the benefits of chemoembolization, sorafenib and regorafenib for patients with liver cancer. He has authored the European Assoaciation for the Study of the Liver, American Association for the Study of Liver Diseases and World Gastroenterology Organization Practice Guidelines and the United Network for Organ Sharing hepatocellular carcinoma (HCC) diagnostic criteria.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 3","pages":"187-189"},"PeriodicalIF":1.2000,"publicationDate":"2016-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0007","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2016-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/8/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Dr Jordi Bruix* speaks to Laura Dormer, Editorial Director: Dr Jordi Bruix is the Head of the Barcelona Clinic Liver Cancer (BCLC) group at the Hospital Clinic (University of Barcelona, Spain) and Director of the Network for Research in Liver and Digestive Disease (CIBEREHD) in the Spanish Research Institute. His research has changed the diagnosis and treatment of liver cancer. Major highlights include: development of the BCLC staging and treatment; development of diagnostic criteria for hepatocellular carcinoma; identification of the value of portal pressure in predicting prognosis after resection; and acting as principal investigator of the Phase III trials that have shown the benefits of chemoembolization, sorafenib and regorafenib for patients with liver cancer. He has authored the European Assoaciation for the Study of the Liver, American Association for the Study of Liver Diseases and World Gastroenterology Organization Practice Guidelines and the United Network for Organ Sharing hepatocellular carcinoma (HCC) diagnostic criteria.

Regorafenib和resce试验:肝细胞癌患者的新二线选择
Jordi Bruix博士*与编辑主任Laura Dormer交谈:Jordi Bruix博士是西班牙巴塞罗那大学医院诊所巴塞罗那诊所肝癌(BCLC)小组的负责人,也是西班牙研究所肝脏和消化系统疾病研究网络(CIBEREHD)的主任。他的研究改变了肝癌的诊断和治疗。主要亮点包括:BCLC分期和治疗的发展;肝细胞癌诊断标准的发展门静脉压力在预测切除后预后中的价值并担任III期试验的首席研究员,该试验显示化疗栓塞、索拉非尼和瑞非尼对肝癌患者的益处。他撰写了欧洲肝脏研究协会,美国肝脏疾病研究协会和世界胃肠病组织实践指南以及器官共享肝细胞癌(HCC)诊断标准联合网络。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hepatic Oncology
Hepatic Oncology ONCOLOGY-
CiteScore
0.40
自引率
0.00%
发文量
4
审稿时长
13 weeks
期刊介绍: Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信